141080 — LigaChem Biosciences Income Statement
0.000.00%
Last trade - 00:00
- KR₩3tn
- KR₩3tn
- KR₩34bn
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 57,500 | 49,394 | 32,157 | 33,412 | 34,146 |
Cost of Revenue | |||||
Gross Profit | 34,811 | 35,565 | 17,698 | 17,849 | 17,797 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 49,288 | 78,888 | 58,954 | 84,027 | 115,298 |
Operating Profit | 8,212 | -29,495 | -26,797 | -50,615 | -81,153 |
Gain / Loss on Sale of Assets | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 13,102 | -8,827 | -20,523 | -47,723 | -75,747 |
Provision for Income Taxes | |||||
Net Income After Taxes | 12,476 | -6,986 | -23,391 | -45,092 | -73,704 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 13,586 | -6,986 | -23,391 | -45,092 | -73,704 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 13,586 | -6,986 | -23,391 | -45,092 | -73,704 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 574 | -315 | -989 | -1,844 | -2,588 |
Dividends per Share |